Analytical and Bioanalytical Chemistry

, Volume 401, Issue 2, pp 463–481

Recent developments in doping testing for erythropoietin

Review

Abstract

The constant development of new erythropoiesis-stimulating agents (ESAs), since the first introduction of recombinant erythropoietin (rhEpo) for clinical use, has also necessitated constant development of methods for detecting the abuse of these substances. Doping with ESAs is prohibited according to the World Anti-Doping Code and its prohibited list of substances and methods. Since the first publication of a direct and urine-based detection method in 2000, which uses changes in the Epo isoform profile as detected by isoelectric focusing in polyacrylamide slab gels (IEF-PAGE), the method has been constantly adapted to the appearance of new ESAs (e.g., Dynepo, Mircera). Blood had to be introduced as an additional matrix, because Mircera (a PEGylated Epo) is best confirmed in serum or plasma after immunoaffinity purification. A Mircera ELISA was developed for fast screening of sera. With the appearance of Dynepo and copy epoetins, the additional application of sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE or equivalent) became necessary. The haematological module of the Athlete Biological Passport is the latest development in multivariable indirect testing for ESA doping. The article summarizes the main strategies currently used in Epo anti-doping testing with special focus on new developments made between 2009 and 2010.

Figure

Recent developments in doping testing for Epo include mass-based methods. The apparent molecular mass of most rhEpos is higher than for uhEpo, which can be shown by SDS-PAGE

Keywords

Erythropoietin (Epo) Doping control Electrophoresis Mass spectrometry ELISA Biological passport Direct and indirect detection 

References

  1. 1.
    Lin FK, Suggs S, Lin CH, Browne JK, Smalling R, Egrie JC, Chen KK, Fox GM, Martin F, Stabinsky Z, Badrawi SM, Lai PH, Goldwasser E (1985) Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA 82:7580–7584CrossRefGoogle Scholar
  2. 2.
    Israels LG, Israels ED (2003) Erythropoiesis: an overview. In: Molineux G, Foote MA, Elliott SG (eds) Erythropoietins and erythropoiesis, 1st edn. Birkhäuser, BaselGoogle Scholar
  3. 3.
    Catlin DH, Hatton CK, Lasne F (2003) Abuse of recombinant erythropoietins by athletes. In: Molineux G, Foote MA, Elliott SG (eds) Erythropoietins and erythropoiesis, 1st edn. Birkhäuser, BaselGoogle Scholar
  4. 4.
    Lasne F, de Ceaurriz J (2000) Recombinant erythropoietin in urine. Nature 405:635CrossRefGoogle Scholar
  5. 5.
    Parisotto R, Gore CJ, Emslie KR, Ashenden MJ, Brugnara C, Howe C, Martin DT, Trout GJ, Hahn AG (2000) A novel method utilising markers of altered erythropoiesis for the detection of recombinant human erythropoietin abuse in athletes. Haematologica 85:564–572Google Scholar
  6. 6.
    World Anti-Doping Agency (2010) The World Anti-Doping Code. The 2011 Prohibited List. International Standard, Montreal. http://www.wada-ama.org/Documents/World_Anti-Doping_Program/WADP-Prohibited-list/To_be_effective/WADA_Prohibited_List_2011_EN.pdf. Accessed 10 January 2011
  7. 7.
    World Anti-Doping Agency (2009) Harmonization of the method for the identification of recombinant erythropoietins (i.e. epoetins) and analogues (e.g. darbepoetin and methoxypolyethylene glycol-epoetin beta), Montreal. http://www.wada-ama.org/Documents/World_Anti-Doping_Program/WADP-IS-Laboratories/WADA_TD2009EPO_EN.pdf. Accessed 6 January 2011
  8. 8.
    Lasne F, Martin L, Crepin N, de Ceaurriz J (2002) Detection of isoelectric profiles of erythropoietin in urine: differentiation of natural and administered recombinant hormones. Anal Biochem 311:119–126CrossRefGoogle Scholar
  9. 9.
    Wide L, Bengtsson C (1990) Molecular charge heterogeneity of human serum erythropoietin. Br J Haematol 76:121–127CrossRefGoogle Scholar
  10. 10.
    Tam RC, Coleman SL, Tiplady RJ, Storring PL, Cotes PM (1991) Comparisons of human, rat and mouse erythropoietins by isoelectric focusing: differences between serum and urinary erythropoietins. Br J Haematol 79:504–511CrossRefGoogle Scholar
  11. 11.
    Wide L, Bengtsson C, Berglund B, Ekblom B (1995) Detection in blood and urine of recombinant erythropoietin administered to healthy men. Med Sci Sports Exerc 27:1569–1576Google Scholar
  12. 12.
    Lasne F, Martin L, Martin JA, de Ceaurriz J (2007) Isoelectric profiles of human erythropoietin are different in serum and urine. Int J Biol Macromol 41:354–357CrossRefGoogle Scholar
  13. 13.
    Lönnberg M, Dehnes Y, Drevin M, Garle M, Lamon S, Leuenberger N, Quach T, Carlsson J (2010) Rapid affinity purification of erythropoietin from biological samples using disposable monoliths. J Chromatogr A 1217:7031–7037CrossRefGoogle Scholar
  14. 14.
    Dehnes Y, Lamon S, Lönnberg M (2010) Erythropoietin (EPO) immunoaffinity columns - a powerful tool for purifying EPO and its recombinant analogues. J Pharm Biomed Anal 53:1028–1032CrossRefGoogle Scholar
  15. 15.
    Lasne F (2001) Double-blotting: a solution to the problem of non-specific binding of secondary antibodies in immunoblotting procedures. J Immunol Meth 253:125–131CrossRefGoogle Scholar
  16. 16.
    Lasne F (2003) Double-blotting: a solution to the problem of nonspecific binding of secondary antibodies in immunoblotting procedures. J Immunol Meth 276:223–226CrossRefGoogle Scholar
  17. 17.
    Hammerl P, Hartl A, Freund J, Thalhamer J (1992) A method for the detection of serologically crossreacting antigens both within and between protein mixtures: the western cross blot. J Immunol Meth 151:299–306CrossRefGoogle Scholar
  18. 18.
    Bajla I, Holländer I, Gmeiner G, Reichel Ch (2005) Quantitative analysis of images in erythropoietin doping control. Med Biol Eng Comput 43:403–409CrossRefGoogle Scholar
  19. 19.
    Bajla I, Holländer I, Minichmayr M, Gmeiner G, Reichel Ch (2005) GASepo - a software solution for quantitative analysis of digital images in Epo doping control. Comput Meth Programs Biomed 80:246–270CrossRefGoogle Scholar
  20. 20.
    Stolc S, Bajla I, 4 (2006) Improvement of band segmentation in Epo images via column shift transformation with cost functions. Med Biol Eng Comput 44:257–274, Erratum in: Med Biol Eng Comput 44:605–7CrossRefGoogle Scholar
  21. 21.
    Segura J, Pascual JA, Gutiérrez-Gallego R (2007) Procedures for monitoring recombinant erythropoietin and analogues in doping control. Anal Bioanal Chem 388:1521–1529CrossRefGoogle Scholar
  22. 22.
    Catlin DH, Breidbach A, Elliott S, Glaspy J (2002) Comparison of the isoelectric focusing patterns of darbepoetin alfa, recombinant human erythropoietin, and endogenous erythropoietin from human urine. Clin Chem 48:2057–2059Google Scholar
  23. 23.
    Schellekens H (2004) Biosimilar epoetins: how similar are they? EJHP 2004(3):43–47Google Scholar
  24. 24.
    Belalcazar V, Ventura R, Segura J, Pascual JA (2008) Clarification on the detection of epoetin delta and epoetin omega using isoelectric focusing. Am J Hematol 83:754CrossRefGoogle Scholar
  25. 25.
    Reichel C, Kulovics R, Jordan V, Watzinger M, Geisendorfer T (2009) SDS-PAGE of recombinant and endogenous erythropoietins: benefits and limitations of the method for application in doping control. Drug Test Anal 1:43–50CrossRefGoogle Scholar
  26. 26.
    Macdougall IC, Ashenden M (2009) Current and upcoming erythropoiesis-stimulating agents, iron products, and other novel anemia medications. Adv Chron Kidney Dis 16:117–130CrossRefGoogle Scholar
  27. 27.
    Lasne F, Martin L, Martin JA, de Ceaurriz J (2009) Detection of continuous erythropoietin receptor activator in blood and urine in anti-doping control. Haematologica 94:888–890CrossRefGoogle Scholar
  28. 28.
    Reichel C (2008) Identification of zinc-alpha-2-glycoprotein binding to clone AE7A5 antihuman EPO antibody by means of nano-HPLC and high-resolution high-mass accuracy ESI-MS/MS. J Mass Spectrom 43:916–923CrossRefGoogle Scholar
  29. 29.
    Rabin OP, Lasne F, Pascual JA, Saugy M, Delbeke FJ, Van Eenoo P (2006) New urinary EPO drug testing method using two-dimensional gel electrophoresis. Clin Chim Acta 373:186–187CrossRefGoogle Scholar
  30. 30.
    Lasne F (2006) No doubt about the validity of the urine test for detection of recombinant human erythropoietin. Blood 108:1778–1779CrossRefGoogle Scholar
  31. 31.
    Khan A, Grinyer J, Truong ST, Breen EJ, Packer NH (2005) New urinary EPO drug testing method using two-dimensional gel electrophoresis. Clin Chim Acta 358:119–130CrossRefGoogle Scholar
  32. 32.
    Khan A, Baker MS (2007) Non-specific binding of monoclonal human erythropoietin antibody AE7A5 to Escherichia coli and Saccharomyces cerevisiae proteins. Clin Chim Acta 379:173–175CrossRefGoogle Scholar
  33. 33.
    Franke WW, Heid H (2006) Pitfalls, errors and risks of false-positive results in urinary EPO drug tests. Clin Chim Acta 373:189–190CrossRefGoogle Scholar
  34. 34.
    Beullens M, Delanghe JR, Bollen M (2006) False-positive detection of recombinant human erythropoietin in urine following strenuous physical exercise. Blood 107:4711–4713CrossRefGoogle Scholar
  35. 35.
    Rabin OP, Lasne F, Pascual JA, Saugy M, Delbeke FJ, Van Eenoo P (2006) New urinary EPO drug testing method using two-dimensional gel electrophoresis. Clin Chim Acta 373:186–187CrossRefGoogle Scholar
  36. 36.
    Catlin D, Green G, Sekera M, Scott P, Starcevic B (2006) False-positive Epo test concerns unfounded. Blood 108:1778CrossRefGoogle Scholar
  37. 37.
    Lasne F (2006) No doubt about the validity of the urine test for detection of recombinant human erythropoietin. Blood 108:1778–1779CrossRefGoogle Scholar
  38. 38.
    Segura J, Pascual JA, Gutiérrez-Gallego R (2007) Procedures for monitoring recombinant erythropoietin and analogues in doping control. Anal Bioanal Chem 388:1521–1529CrossRefGoogle Scholar
  39. 39.
    Lamon S, Martin L, Robinson N, Saugy M, Ceaurriz J, Lasne F (2009) Effects of exercise on the isoelectric patterns of erythropoietin. Clin J Sport Med 19:311–315CrossRefGoogle Scholar
  40. 40.
    Lasne F (2009) Erythropoietin doping – detection in urine. In: Fourcroy JL (ed) Pharmacology, doping and sports. Routledge, LondonGoogle Scholar
  41. 41.
    Lasne F, Thioulouse J, Martin L, de Ceaurriz J (2007) Detection of recombinant human erythropoietin in urine for doping analysis: interpretation of isoelectric profiles by discriminant analysis. Electrophoresis 28:1875–1881CrossRefGoogle Scholar
  42. 42.
    Lamon S, Boccard J, Sottas PE, Glatz N, Wuerzner G, Robinson N, Saugy M (2010) IEF pattern classification-derived criteria for the identification of epoetin-delta in urine. Electrophoresis 31:1918–1924CrossRefGoogle Scholar
  43. 43.
    Ashenden M, Varlet-Marie E, Lasne F, Audran M (2006) The effects of microdose recombinant human erythropoietin regimens in athletes. Haematologica 91:1143–1144Google Scholar
  44. 44.
    Lasne F, Martin L, Martin JA (2010) A fast preparative method for detection of recombinant erythropoietin in blood samples. Drug Test Anal 2:494–495CrossRefGoogle Scholar
  45. 45.
    Reichel C, Benetka E, Geisendorfer T, Scheiblhofer V, Abzieher F (2010) The interference of heparin on IEF-PAGE of erythropoietins. Drug Test Anal 2:568–575CrossRefGoogle Scholar
  46. 46.
    Catlin DH, Hatton CK (2009) Abuse of recombinant erythropoietins and blood products by athletes. In: Elliott SG, Foote MA, Molineux G (eds) Erythropoietins, erythropoietic factors and erythropoiesis, 2nd edn. Birkhäuser, BaselGoogle Scholar
  47. 47.
    Reichel C (2010) Practicing IEF-PAGE of EPO: the impact of detergents and sample application methods on analytical performance in doping control. Drug Test Anal 2:603–619CrossRefGoogle Scholar
  48. 48.
    Lasne F, Popot MA, Varlet-Marie E, Martin L, Martin JA, Bonnaire Y, Audran M, de Ceaurriz J (2005) Detection of recombinant epoetin and darbepoetin alpha after subcutaneous administration in the horse. J Anal Toxicol 29:835–837Google Scholar
  49. 49.
    Bartlett C, Clancy GJ, Cowan DA, Healy JF (2006) Detection of the administration of human erythropoietin (HuEPO) to canines. J Anal Toxicol 30:663–669Google Scholar
  50. 50.
    Catlin DH, Maylin GA, Benchaar S, Neades SM, Timmons MS, McKeever KH (2009) Detection of pegylated epoetin β in horse plasma after intravenous administration. Comp Exerc Physiol 6:105–108CrossRefGoogle Scholar
  51. 51.
    Kung CK, Goldwasser E (1997) A probable conformational difference between recombinant and urinary erythropoietins. Proteins 28:94–98CrossRefGoogle Scholar
  52. 52.
    Masuda S, Okano M, Yamagishi K, Nagao M, Ueda M, Sasaki R (1994) A novel site of erythropoietin production. Oxygen-dependent production in cultured rat astrocytes. J Biol Chem 269:19488–19493Google Scholar
  53. 53.
    Skibeli V, Nissen-Lie G, Torjesen P (2001) Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin. Blood 98:3626–3634CrossRefGoogle Scholar
  54. 54.
    Skibeli V, Nissen-Lie G (2003) Immunomagnetic extraction as a tool for the analysis of human serum erythropoietin. DYNALogue 1:13–15Google Scholar
  55. 55.
    Desharnais P, Ayotte C (2007) Towards the screening of urinary Epo by SDS-PAGE analysis. In: Schänzer et al (eds) Recent advances in doping analysis (15). Sportverlag Strauss, CologneGoogle Scholar
  56. 56.
    Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA (2003) Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 31:290–299CrossRefGoogle Scholar
  57. 57.
    Balaguer E, Neusüss C (2006) Intact glycoform characterization of erythropoietin-alfa and erythropoietin-beta by CZE-ESI-TOF-MS. Chromatographia 64:351–357CrossRefGoogle Scholar
  58. 58.
    Reichel C, Gmeiner G (2010) Erythropoietins and analogues. In: Thieme D, Hemmersbach P (eds) Doping in sports (Handbook of Experimental Pharmacology 195). Springer, BerlinGoogle Scholar
  59. 59.
    Reichel C, Kulovics R, Jordan V, Watzinger M, Geisendorfer T (2009) SDS-PAGE of recombinant and endogenous erythropoietins: benefits and limitations of the method for application in doping control. Drug Test Anal 1:43–50CrossRefGoogle Scholar
  60. 60.
    Kohler M, Ayotte C, Desharnais P, Flenker U, Lüdke S, Thevis M, Völker-Schänzer E, Schänzer W (2007) Discrimination of recombinant and endogenous urinary erythropoietin by calculating relative mobility values from SDS gels. Int J Sports Med 29:1–6CrossRefGoogle Scholar
  61. 61.
    Voss S, Lüdke A, Romberg S, Schänzer E, Flenker U, deMarees M, Achtzehn S, Mester J, Schänzer W (2010) Effects of high intensity exercise on isoelectric profiles and SDS-PAGE mobility of erythropoietin. Int J Sports Med 31:367–371CrossRefGoogle Scholar
  62. 62.
    Gmeiner G, Reichel C, Kulovics R, Scheiblhofer V (2010) Defending Dynepo detection. Drug Test Anal 2:526–532CrossRefGoogle Scholar
  63. 63.
    Llop E, Gutiérrez-Gallego R, Segura J, Mallorquí J, Pascual JA (2008) Structural analysis of the glycosylation of gene-activated erythropoietin (epoetin delta, Dynepo). Anal Biochem 383:243–254CrossRefGoogle Scholar
  64. 64.
    Reichel C, Abzieher F, Geisendorfer T (2009) SARCOSYL-PAGE: a new method for the detection of Mircera- and EPO-doping in blood. Drug Test Anal 1:494–504CrossRefGoogle Scholar
  65. 65.
    Schlags W, Lachmann B, Walther M, Kratzel M, Noe CR (2002) Two-dimensional electrophoresis of recombinant human erythropoietin: a future method for the European Pharmacopoeia? Proteomics 2:679–682CrossRefGoogle Scholar
  66. 66.
    Caldini A, Moneti G, Fanelli A, Bruschettini A, Mercurio S, Pieraccini G, Cini E, Ognibene A, Luceri F, Messeri G (2003) Epoetin alpha, epoetin beta and darbepoetin alfa: two-dimensional gel electrophoresis isoforms characterization and mass spectrometry analysis. Proteomics 3:937–941CrossRefGoogle Scholar
  67. 67.
    Llop E, Gallego RG, Belalcazar V, Gerwig GJ, Kamerling JP, Segura J, Pascual JA (2007) Evaluation of protein N-glycosylation in 2-DE: erythropoietin as a study case. Proteomics 7:4278–4291CrossRefGoogle Scholar
  68. 68.
    Khan A, Grinyer J, Truong ST, Breen EJ, Packer NH (2005) New urinary EPO drug testing method using two-dimensional gel electrophoresis. Clin Chim Acta 358:119–130CrossRefGoogle Scholar
  69. 69.
    Görg A, Drews O, Lück C, Weiland F, Weiss W (2009) 2-DE with IPGs. Electrophoresis 30(Suppl 1):S122–S132CrossRefGoogle Scholar
  70. 70.
    Wide L, Wikström B, Eriksson K (2003) A new principle suggested for detection of darbepoetin-alpha (NESP) doping. Ups J Med Sci 108:229–238CrossRefGoogle Scholar
  71. 71.
    Egrie JC, Browne JK (2001) Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 16(Suppl 3):3–13Google Scholar
  72. 72.
    Giménez E, de Bolós C, Belalcazar V, Andreu D, Borrás E, De la Torre BG, Barbosa J, Segura J, Pascual JA (2007) Anti-EPO and anti-NESP antibodies raised against synthetic peptides that reproduce the minimal amino acid sequence differences between EPO and NESP. Anal Bioanal Chem 388:1531–1538CrossRefGoogle Scholar
  73. 73.
    Giampaoli S, Facciabene A, Mennuni C (2003) A protocol to guide development of a sensitive ELISA for canine erythropoietin. Vet Clin Pathol 32:199–201CrossRefGoogle Scholar
  74. 74.
    Mallorquí J, Gutiérrez-Gallego R, Segura J, de Bolòs C, Pascual JA (2010) New screening protocol for recombinant human erythropoietins based on differential elution after immunoaffinity purification. J Pharm Biomed Anal 51:255–259CrossRefGoogle Scholar
  75. 75.
    Mallorquí J, Llop E, de Bolòs C, Gutiérrez-Gallego R, Segura J, Pascual JA (2010) Purification of erythropoietin from human plasma samples using an immunoaffinity well plate. J Chromatogr B Anal Technol Biomed Life Sci 878:2117–2122CrossRefGoogle Scholar
  76. 76.
    Van Maerken T, Dhondt A, Delanghe JR (2010) A rapid and simple assay to determine pegylated erythropoietin in human serum. J Appl Physiol 108:800–803CrossRefGoogle Scholar
  77. 77.
    Lamon S, Giraud S, Egli L, Smolander J, Jarsch M, Stubenrauch KG, Hellwig A, Saugy M, Robinson N (2009) A high-throughput test to detect C.E.R.A. doping in blood. J Pharm Biomed Anal 50:954–958CrossRefGoogle Scholar
  78. 78.
    Fan Q, Leuther KK, Holmes CP, Fong KL, Zhang J, Velkovska S, Chen MJ, Mortensen RB, Leu K, Green JM, Schatz PJ, Woodburn KW (2006) Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia. Exp Hematol 34:1303–1311CrossRefGoogle Scholar
  79. 79.
    Lönnberg M, Carlsson J (2006) Lab-on-a-chip technology for determination of protein isoform profiles. J Chromatogr A 1127:175–182CrossRefGoogle Scholar
  80. 80.
    Lönnberg M, Drevin M, Carlsson J (2008) Ultra-sensitive immunochromatographic assay for quantitative determination of erythropoietin. J Immunol Meth 339:236–244CrossRefGoogle Scholar
  81. 81.
    Carlsson J, Lönnberg M, Garle M (unknown) Membrane Assisted Isoform Immunoassay (MAIIA I) a unique method for rapid detection of rhEPO in doping, Montreal. http://www.wada-ama.org/Documents/Science_Medicine/Funded_Research_Projects/Completed_Projects/2005/05A1JC-Carlsson.pdf. Accessed 9 January 2011
  82. 82.
    MAIIA Diagnostics (2010) Rapid EPO MAIIA doping test, Upsala. http://www.maiiadiagnostics.com/research/epo_doping_test.pdf. Accessed 9 January 2011
  83. 83.
    Lönnberg M, Carlsson J (2000) Membrane assisted isoform immunoassay. A rapid method for the separation and determination of protein isoforms in an integrated immunoassay. J Immunol Methods 246:25–36CrossRefGoogle Scholar
  84. 84.
    Franco Fraguas L, Carlsson J, Lönnberg M (2008) Lectin affinity chromatography as a tool to differentiate endogenous and recombinant erythropoietins. J Chromatogr A 1212:82–88CrossRefGoogle Scholar
  85. 85.
    Carlsson J, Garle M, Lönnberg M (2008) MAIIA method for EPO detection, Montreal. http://www.wada-ama.org/Documents/Science_Medicine/Scientific%20Events/Tokyo_Symposium_2009/WADA_Tokyo_Symposium_Dr.Carlsson-Dr.L%c3%b6nnberg-Dr.Garle.pdf. Accessed 9 January 2011
  86. 86.
    MAIIA Diagnostics (2010) Carbon Black Nano-Strings, Upsala. http://www.maiiadiagnostics.com/files/Directions%20for%20Use%20-%20Carbon%20Black%20Nano-Strings,%20100%20nm.pdf. Accessed 9 January 2011
  87. 87.
    Lönnberg M, Carlsson J (2001) Quantitative detection in the attomole range for immunochromatographic tests by means of a flatbed scanner. Anal Biochem 293:224–231CrossRefGoogle Scholar
  88. 88.
    MAIIA Diagnostics (2010) Scanner Detection Instruction, Upsala. http://www.maiiadiagnostics.com/files/Directions%20for%20Use%20-%20Scanner%20Detection.pdf. Accessed 9 January 2011
  89. 89.
    MAIIA Diagnostics (2010) EPO Quantification Kit, Upsala. http://www.maiiadiagnostics.com/files/Directions%20for%20Use%20-%20EPO%20Quantification%20Kit.pdf. Accessed 9 January 2011
  90. 90.
    Lasne F, Martin L, de Ceaurriz J (2005) Active urine and detection of recombinant erythropoietin. In: Schänzer et al (eds) Recent advances in doping analysis (13). Sportverlag Strauss, CologneGoogle Scholar
  91. 91.
    Belalcazar V, Pascual JA, Abanades S, Farré M, de la Torre R (2005) Stability of EPO in urine stabilized by sodium azide. In: Schänzer et al (eds) Recent advances in doping analysis (13). Sportverlag Strauss, CologneGoogle Scholar
  92. 92.
    Imai N, Higuchi M, Kawamura A, Tomonoh K, Oh-Eda M, Fujiwara M, Shimonaka Y, Ochi N (1990) Physicochemical and biological characterization of asialoerythropoietin. Suppressive effects of sialic acid in the expression of biological activity of human erythropoietin in vitro. Eur J Biochem 194:457–462CrossRefGoogle Scholar
  93. 93.
    Yanagawa S, Hirade K, Ohnota H, Sasaki R, Chiba H, Ueda M, Goto M (1984) Isolation of human erythropoietin with monoclonal antibodies. J Biol Chem 259:2707–2710Google Scholar
  94. 94.
    Belalcazar V, Gutiérrez Gallego R, Llop E, Segura J, Pascual JA (2006) Assessing the instability of the isoelectric focusing patterns of erythropoietin in urine. Electrophoresis 27:4387–4395CrossRefGoogle Scholar
  95. 95.
    Anielski P, Schwenke D, Monecke S, Jacobs E, Thieme D (2009) Bacterial proteases in urine samples – effects on EPO analysis? In: Schänzer et al (eds) Recent advances in doping analysis (17). Sportverlag Strauss, CologneGoogle Scholar
  96. 96.
    Thevis M, Maurer J, Kohler M, Geyer H, Schänzer W (2007) Proteases in doping control analysis. Int J Sports Med 28:545–549CrossRefGoogle Scholar
  97. 97.
    Thomas A, Kohler M, Walpurgis K, Schänzer W, Thevis M (2009) Proteolysis and autolysis of proteases and the detection of degradation products in doping control. Drug Test Anal 1:81–86CrossRefGoogle Scholar
  98. 98.
    Kohler M, Thomas A, Geyer H, Horta L, Schänzer W, Thevis M (2009) Detection of the protease bacillolysin in doping-control urine samples. Drug Test Anal 1:143–145CrossRefGoogle Scholar
  99. 99.
    Lamon S, Robinson N, Sottas PE, Henry H, Kamber M, Mangin P, Saugy M (2007) Possible origins of undetectable EPO in urine samples. Clin Chim Acta 385:61–66CrossRefGoogle Scholar
  100. 100.
    Tsivou M, Dimopoulou HA, Leontiou IP, Georgakopoulos DG, Koupparis MA, Atta-Politou J, Georgakopoulos CG (2010) Stabilization of human urine doping control samples: III. Recombinant human erythropoietin. Clin Chim Acta 411:448–452CrossRefGoogle Scholar
  101. 101.
    Sanchis-Gomar F, Martinez-Bello VE, Nascimento AL, Gomez-Cabrera MC, Viña J (2010) Alternate methods to prevent protease use as a masking agent in sport. J Sci Med Sport 13:473–474CrossRefGoogle Scholar
  102. 102.
    Sasaki H, Bothner B, Dell A, Fukuda M (1987) Carbohydrate structure of erythropoietin expressed in Chinese hamster ovary cells by a human erythropoietin cDNA. J Biol Chem 262:12059–12076Google Scholar
  103. 103.
    Recny MA, Scoble HA, Kim Y (1987) Structural characterization of natural human urinary and recombinant DNA-derived erythropoietin. Identification of des-arginine 166 erythropoietin. J Biol Chem 262:17156–17163Google Scholar
  104. 104.
    Takeuchi M, Takasaki S, Miyazaki H, Kato T, Hoshi S, Kochibe N, Kobata A (1988) Comparative study of the asparagine-linked sugar chains of human erythropoietins purified from urine and the culture medium of recombinant Chinese hamster ovary cells. J Biol Chem 263:3657–3663Google Scholar
  105. 105.
    Rahbek-Nielsen H, Roepstorff P, Reischl H, Wozny M, Koll H, Haselbeck A (1997) Glycopeptide profiling of human urinary erythropoietin by matrix-assisted laser desorption/ionization mass spectrometry. Mass Spectrom 32:948–958CrossRefGoogle Scholar
  106. 106.
    Rush RS, Derby PL, Smith DM, Merry C, Rogers G, Rohde MF, Katta V (1995) Microheterogeneity of erythropoietin carbohydrate structure. Anal Chem 67:1442–1452CrossRefGoogle Scholar
  107. 107.
    Hokke CH, Bergwerff AA, van Dedem GW, van Oostrum J, Kamerling JP, Vliegenthart JF (1990) Sialylated carbohydrate chains of recombinant human glycoproteins expressed in Chinese hamster ovary cells contain traces of N-glycolylneuraminic acid. FEBS Lett 275:9–14CrossRefGoogle Scholar
  108. 108.
    Hokke CH, Bergwerff AA, Van Dedem GW, Kamerling JP, Vliegenthart JF (1995) Structural analysis of the sialylated N- and O-linked carbohydrate chains of recombinant human erythropoietin expressed in Chinese hamster ovary cells. Sialylation patterns and branch location of dimeric N-acetyllactosamine units. Eur J Biochem 228:981–1008CrossRefGoogle Scholar
  109. 109.
    Nimtz M, Martin W, Wray V, Klöppel KD, Augustin J, Conradt HS (1993) Structures of sialylated oligosaccharides of human erythropoietin expressed in recombinant BHK-21 cells. Eur J Biochem 213:39–56CrossRefGoogle Scholar
  110. 110.
    Nimtz M, Wray V, Rüdiger A, Conradt HS (1995) Identification and structural characterization of a mannose-6-phosphate containing oligomannosidic N-glycan from human erythropoietin secreted by recombinant BHK-21 cells. FEBS Lett 365:203–208CrossRefGoogle Scholar
  111. 111.
    Kawasaki N, Haishima Y, Ohta M, Itoh S, Hyuga M, Hyuga S, Hayakawa T (2001) Structural analysis of sulfated N-linked oligosaccharides in erythropoietin. Glycobiology 11:1043–1049CrossRefGoogle Scholar
  112. 112.
    Kawasaki N, Ohta M, Itoh S, Hyuga M, Hyuga S, Hayakawa T (2002) Usefulness of sugar mapping by liquid chromatography/mass spectrometry in comparability assessments of glycoprotein products. Biologicals 30:113–123CrossRefGoogle Scholar
  113. 113.
    Ohta M, Kawasaki N, Itoh S, Hayakawa T (2002) Usefulness of glycopeptide mapping by liquid chromatography/mass spectrometry in comparability assessment of glycoprotein products. Biologicals 30:235–244CrossRefGoogle Scholar
  114. 114.
    Guan F, Uboh CE, Soma LR, Birks E, Chen J, Mitchell J, You Y, Rudy J, Xu F, Li X, Mbuy G (2007) LC-MS/MS method for confirmation of recombinant human erythropoietin and darbepoetin alpha in equine plasma. Anal Chem 79:4627–4635CrossRefGoogle Scholar
  115. 115.
    Guan F, Uboh CE, Soma LR, Birks E, Chen J, You Y, Rudy J, Li X (2008) Differentiation and identification of recombinant human erythropoietin and darbepoetin Alfa in equine plasma by LC-MS/MS for doping control. Anal Chem 80:3811–3817CrossRefGoogle Scholar
  116. 116.
    Guan F, Uboh CE, Soma LR, Birksz E, Chen J (2009) Identification of darbepoetin alfa in human plasma by liquid chromatography coupled to mass spectrometry for doping control. Int J Sports Med 30:80–86CrossRefGoogle Scholar
  117. 117.
    Yu NH, Ho EN, Wan TS, Wong AS (2010) Doping control analysis of recombinant human erythropoietin, darbepoetin alfa and methoxy polyethylene glycol-epoetin beta in equine plasma by nano-liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem 396:2513–2521CrossRefGoogle Scholar
  118. 118.
    Chang Y, Maylin GM, Matsumoto G, Neades SM, Catlin DH (2010) Screen and confirmation of PEG-epoetin β in equine plasma. Drug Test Anal. 2010 Dec 29. [Epub]Google Scholar
  119. 119.
    Guan F, Uboh CE, Soma LR, Maylin G, Jiang Z, Chen J (2010) Confirmatory analysis of continuous erythropoietin receptor activator and erythropoietin analogues in equine plasma by LC-MS for doping control. Anal Chem 82:9074–9081CrossRefGoogle Scholar
  120. 120.
    Wrighton NC, Farrell FX, Chang R, Kashyap AK, Barbone FP, Mulcahy LS, Johnson DL, Barrett RW, Jolliffe LK, Dower WJ (1996) Small peptides as potent mimetics of the protein hormone erythropoietin. Science 273:458–464CrossRefGoogle Scholar
  121. 121.
    Wrighton NC, Balasubramanian P, Barbone FP, Kashyap AK, Farrell FX, Jolliffe LK, Barrett RW, Dower WJ (1997) Increased potency of an erythropoietin peptide mimetic through covalent dimerization. Nat Biotechnol 15:1261–1265CrossRefGoogle Scholar
  122. 122.
    Johnson DL, Farrell FX, Barbone FP, McMahon FJ, Tullai J, Kroon D, Freedy J, Zivin RA, Mulcahy LS, Jolliffe LK (1997) Amino-terminal dimerization of an erythropoietin mimetic peptide results in increased erythropoietic activity. Chem Biol 4:939–950CrossRefGoogle Scholar
  123. 123.
    Wiecek A, Nieszporek T, Chudek J (2007) Perspectives in the treatment of renal anaemia new concepts and new drugs. Prilozi 28:225–237Google Scholar
  124. 124.
    Macdougall IC (2008) Hematide, a novel peptide-based erythropoiesis-stimulating agent for the treatment of anemia. Curr Opin Investig Drugs 9:1034–1047Google Scholar
  125. 125.
    Perugini M, Varelias A, Sadlon T, D'Andrea RJ (2009) Hematopoietic growth factor mimetics: from concept to clinic. Cytokine Growth Factor Rev 20:87–94CrossRefGoogle Scholar
  126. 126.
    Stead RB, Lambert J, Wessels D, Iwashita JS, Leuther KK, Woodburn KW, Schatz PJ, Okamoto DM, Naso R, Duliege AM (2006) Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers. Blood 108:1830–1834CrossRefGoogle Scholar
  127. 127.
    Macdougall IC, Rossert J, Casadevall N, Stead RB, Duliege AM, Froissart M, Eckardt KU (2009) A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. N Engl J Med 361:1848–1855CrossRefGoogle Scholar
  128. 128.
    Thevis M, Thomas A, Kohler M, Beuck S, Schänzer W (2009) Emerging drugs: mechanism of action, mass spectrometry and doping control analysis. J Mass Spectrom 44:442–460CrossRefGoogle Scholar
  129. 129.
    World Anti-Doping Agency (2010) Athlete biological passport. Operating guidelines and compilation of required elements, Montreal. http://www.wada-ama.org/Documents/Science_Medicine/Athlete_Biological_Passport/WADA_AthletePassport_OperatingGuidelines_FINAL_EN_2.1.pdf. Accessed 9 January 2011
  130. 130.
    Gore CJ, Parisotto R, Ashenden MJ, Stray-Gundersen J, Sharpe K, Hopkins W, Emslie KR, Howe C, Trout GJ, Kazlauskas R, Hahn AG (2003) Second-generation blood tests to detect erythropoietin abuse by athletes. Haematologica 88:333–344Google Scholar
  131. 131.
    Sharpe K, Ashenden MJ, Schumacher YO (2006) A third generation approach to detect erythropoietin abuse in athletes. Haematologica 91:356–363Google Scholar
  132. 132.
    Sottas PE, Robinson N, Giraud S, Taroni F, Kamber M, Mangin P, Saugy M (2006) Statistical classification of abnormal blood profiles in athletes. Int J Biostatistics 2(1):article 3Google Scholar
  133. 133.
    Sottas PE, Robinson N, Saugy M, Niggli O (2008) A forensic approach to the interpretation of blood doping markers. Law Probab Risk 7:191–210CrossRefGoogle Scholar
  134. 134.
    Sottas PE, Robinson N, Saugy M (2010) The Athlete’s biological passport and indirect markers of blood doping. In: Thieme D, Hemmersbach P (eds) Doping in sports (Handbook of Experimental Pharmacology 195). Springer, BerlinGoogle Scholar
  135. 135.
    Mansour MM, Azzazy HM (2009) The hunt for gene dopers. Drug Test Anal 1:311–322CrossRefGoogle Scholar
  136. 136.
    Azzazy HM, Mansour MM, Christenson RH (2009) Gene doping: of mice and men. Clin Biochem 42:435–441CrossRefGoogle Scholar
  137. 137.
    Azzazy HM. Gene doping. In: Thieme D, Hemmersbach P (eds) Doping in Sports (Handbook of Experimental Pharmacology 195). Springer, BerlinGoogle Scholar
  138. 138.
    Lasne F, Martin L, de Ceaurriz J, Larcher T, Moullier P, Chenuaud P (2004) “Genetic Doping” with erythropoietin cDNA in primate muscle is detectable. Mol Ther 10:409–410CrossRefGoogle Scholar
  139. 139.
    Stieger K, Le Meur G, Lasne F, Weber M, Deschamps JY, Nivard D, Mendes-Madeira A, Provost N, Martin L, Moullier P, Rolling F (2006) Long-term doxycycline-regulated transgene expression in the retina of nonhuman primates following subretinal injection of recombinant AAV vectors. Mol Ther 13:967–975CrossRefGoogle Scholar
  140. 140.
    Menzel O, Birraux J, Wildhaber BE, Jond C, Lasne F, Habre W, Trono D, Nguyen TH, Chardot C (2009) Biosafety in ex vivo gene therapy and conditional ablation of lentivirally transduced hepatocytes in nonhuman primates. Mol Ther 17:1754–1760CrossRefGoogle Scholar
  141. 141.
    Beiter T, Zimmermann M, Fragasso A, Armeanu S, Lauer UM, Bitzer M, Su H, Young WL, Niess AM, Simon P (2008) Establishing a novel single-copy primer-internal intron-spanning PCR (spiPCR) procedure for the direct detection of gene doping. Exerc Immunol Rev 14:73–85Google Scholar
  142. 142.
    Beiter T, Zimmermann M, Fragasso A, Hudemann J, Niess AM, Bitzer M, Lauer UM, Simon P (2010) Direct and long-term detection of gene doping in conventional blood samples. Gene Ther [Epub]Google Scholar
  143. 143.
    Baoutina A, Coldham T, Bains GS, Emslie KR (2010) Gene doping detection: evaluation of approach for direct detection of gene transfer using erythropoietin as a model system. Gene Ther 17:1022–1032CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  1. 1.Doping Control Laboratory, AIT Seibersdorf LaboratoriesSeibersdorfAustria

Personalised recommendations